MRK
25
2
BAC
38
3
AZO
46
3
HPE
48
2
M
40
3
MS
64
3
DVA
62
5
T
32
2
NDAQ
46
2
HAL
40
11
AES
47
4
JNJ
30
4
V
70
14
PFG
27
7
THC
52
9
TROW
37
8
MTCH
62
22
MKC
54
3
HCP
54
2
COP
36
2
MRK
25
2
BAC
38
3
AZO
46
3
HPE
48
2
M
40
3
MS
64
3
DVA
62
5
T
32
2
NDAQ
46
2
HAL
40
11
AES
47
4
JNJ
30
4
V
70
14
PFG
27
7
THC
52
9
TROW
37
8
MTCH
62
22
MKC
54
3
HCP
54
2
COP
36
2
Financhill
Back

Denali Therapeutics Quote, Financials, Valuation and Earnings

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here
Sell
6

DNLI
Denali Therapeutics

Last Price:
$21.48
Seasonality Move:
-13.89%

7 Day Trial

ALL ACCESS PASS

$ 7

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Denali Therapeutics Price Quote

$21.48
+0.02 (+-0.05%)
(Updated: December 21, 2024 at 5:23 AM ET)

Denali Therapeutics Key Stats

Sell
6
Denali Therapeutics (DNLI) is a Sell
Day range:
$21.00 - $22.21
52-week range:
$14.56 - $33.33
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
9.85
P/B ratio:
2.34%
Volume:
2.5M
Avg. volume:
978.4K
1-year change:
1.37%
Market cap:
$3.1B
Revenue:
$330.5M
EPS:
$-2.76

How Much Does Denali Therapeutics Make?

Data Unavailable

Is Denali Therapeutics Growing As A Company?

Data Unavailable

Denali Therapeutics Stock Price Performance

What Is Denali Therapeutics 52-Week High & Low?

Denali Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Denali Therapeutics?

Data Unavailable

Is Denali Therapeutics Cash Flow Positive?

Data Unavailable

Denali Therapeutics Return On Invested Capital

Data Unavailable

Denali Therapeutics Earnings Date & Stock Price

Denali Therapeutics Competitors

  • Who Are Denali Therapeutics's Competitors?
    Below is a list of companies who compete with Denali Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Protalix BioTherapeutics Inc (PLX)

Denali Therapeutics Dividend Yield

Data Unavailable

Denali Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.3%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 42.77
Upside from Last Price: 99.3%

Major Shareholders

Data Unavailable